GE HEALTHCARE TECHNOLOGIES INC
GE HealthCare Technologies Inc. (GEHC) is a global medical technology and services company focused on diagnostic imaging, ultrasound, patient monitoring, life‑sciences tools and bioprocessing, and healthcare IT. With a market capitalisation around $34.7 billion, the business combines capital equipment sales with recurring revenue from service contracts, consumables and software – a mix that can smooth cyclicality in equipment purchases. Key growth drivers include demand for imaging and diagnostics, expansion of bioprocessing for biologics, and adoption of digital and AI tools to improve workflows. Investors should be aware of sensitivity to hospital and clinic capital spending cycles, competitive pressures, reimbursement and regulatory risk, and supply‑chain dynamics. Management execution and capital allocation also matter for returns. This summary is educational only, not personalised advice: values can rise and fall and past performance is not a guide to the future. Check up‑to‑date filings and consult a financial adviser when assessing suitability for your portfolio.
Why It's Moving
GE HealthCare Sparks Rally with 2026 Profit Outlook Beating Expectations on Surging Medical Device Demand
- Profit guidance for 2026 tops consensus estimates, highlighting sustained strength in imaging and diagnostics equipment sales.
- Seven analysts lifted earnings projections in recent weeks, pushing the consensus to $5.01 per share with a track record of +7.5% surprises.
- Wall Street's strong buy consensus reflects optimism over GEHC's positioning in high-growth medical tech amid favorable sector tailwinds.
GE HealthCare Sparks Rally with 2026 Profit Outlook Beating Expectations on Surging Medical Device Demand
- Profit guidance for 2026 tops consensus estimates, highlighting sustained strength in imaging and diagnostics equipment sales.
- Seven analysts lifted earnings projections in recent weeks, pushing the consensus to $5.01 per share with a track record of +7.5% surprises.
- Wall Street's strong buy consensus reflects optimism over GEHC's positioning in high-growth medical tech amid favorable sector tailwinds.
When is the next earnings date for GE HEALTHCARE TECHNOLOGIES INC (GEHC)?
GE HealthCare Technologies (GEHC) is scheduled to report its next earnings on Wednesday, April 29, 2026, before market open. This release will cover the first quarter of 2026 (Q1 2026), with a conference call at 8:30 a.m. ET. Investors should monitor the company's Investor Relations site for the earnings release and webcast details.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying GE Healthcare's stock, expecting its value to rise significantly.
Financial Health
GE Healthcare is showing strong revenue and cash flow, indicating solid financial performance.
Dividend
GE Healthcare's low dividend yield of 0.23% indicates limited returns for dividend-seeking investors. If you invested $1000, you would be paid $2.30 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring GEHC
Healthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketARK Innovation ETF: What's Next for Africa's Growth?
Africa's digital economy is rapidly expanding, creating demand for cutting-edge technologies in finance, healthcare, and energy. This basket offers potential exposure to US-listed companies leading the disruptive innovation trends that are shaping the continent's future.
Published: September 15, 2025
Explore BasketHealthcare's Efficiency Imperative
UnitedHealth Group's recent profit miss, driven by high medical costs, has triggered a major cost-cutting initiative across the company. This move signals a broader industry trend, creating an investment opportunity in companies that provide AI and technology solutions to help healthcare organizations improve efficiency and reduce operational expenses.
Published: July 30, 2025
Explore BasketHealthcare's Compliance Catalyst
The Department of Justice's investigation into UnitedHealth's billing practices is increasing pressure on the entire healthcare industry to ensure compliance. This regulatory focus creates an investment opportunity in companies that provide specialized technology for transparent and accurate medical billing.
Published: July 26, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diagnostics and Imaging
Imaging equipment drives sales and higher‑margin service revenue; technological upgrades and AI could support demand, though hospital budgets and reimbursement affect timing.
Life Sciences Growth
Bioprocessing and tools for biologics offer expansion opportunities as biologics production rises, but competition and capital intensity can affect margins.
Global Service Network
Recurring revenue from service contracts and consumables provides stability and customer ties, yet geographic exposure and supply chains can influence performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.